Market News & Trends
Pfizer Awards Flagship OTC Product Manufacturing Contract to Catalent
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, recently announced…
New Phase III Data Show Optune in Combination With Second-Line Chemotherapy is Superior
Novocure recently announced new Phase III data showing that glioblastoma patients who received TTFields in combination with chemotherapy at first recurrence lived significantly longer than…
LSP & Bristol-Myers Squibb Enter Strategic Collaboration for Life Sciences Innovation
LSP (Life Sciences Partners) recently announced a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough…
Novozymes Half-Life Extension Technology Embraced by Paras Biopharmaceuticals to Develop New Biobetter
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version (a biobetter) of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease…
Summit Therapeutics Announces Novel Antibiotic Ridinilazole Achieves Statistical Superiority Over Vancomycin
Summit Therapeutics plc recently announced the success of CoDIFy, a Phase II proof- of-concept clinical trial that evaluated the novel, oral antibiotic, ridinilazole (SMT19969) against…
Presage Biosciences In-Licenses Clinical-Stage Drug Program
Presage Biosciences recently announced it has in-licensed voruciclib, its first clinical- stage drug program. Voruciclib is an oral CDK inhibitor that has been in clinical…
Idera to Collaborate With GSK to Identify Third-Generation Antisense Molecules
Idera Pharmaceuticals, Inc. recently announced it has entered into an exclusive worldwide collaboration and license agreement with GSK to research, develop, and commercialize selected molecules…
Global Type 1 Diabetes Mellitus Market Value Will Exceed $7 Billion
The Type 1 Diabetes Mellitus (T1DM) market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan will…
UPM Pharmaceuticals Seeking to Fill 8 Positions
Qualified candidates please reference job title and email resume and salary requirements to:humanresources@upm-inc.com UPM Pharmaceuticals, Inc. (www.upm-inc.com), a growing contract drug development and manufacturing…
GENFIT Announces Pivotal Phase III Clinical Trial
GENFIT recently announced the design of the global Phase III trial to evaluate the benefits of Elafibranor treatment on NASH patients. The pivotal trial will…
Baxter Completes Capacity Expansion to Support Oncology Contract Manufacturing Services
Baxter International Inc.’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, recently announced it has completed an approximately 1,800-square-meter…
Xenetic Biosciences Enters Into Asset Purchase Agreement
Xenetic Biosciences, Inc. recently announced it has entered into an Asset Purchase Agreement with AS Kevelt and OJSC Pharmsynthez. Pursuant to the APA, the Sellers…
Adare Pharmaceuticals Partners With Cincinnati Children’s on Innovation Fund
Adare Pharmaceuticals, Inc. and the Cincinnati Children’s Hospital Medical Center recently announced they are partnering together on an Innovation Fund, which will focus on optimizing…
Catalent Biologics Expands Analytical & Process Development Capabilities
Catalent Pharma Solutions recently announced the multi-site expansion of its analytical and process development capabilities for biologics. These investments include a significant expansion of bioassay…
Concert Pharmaceuticals Achieves $2-Million Milestone From Avanir Pharmaceuticals
Concert Pharmaceuticals, Inc. recently announced it has achieved a $2-million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the progression of…
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
Aptose Biosciences Inc. recently announced two collaborations that will provide exclusive access to new epigenetic therapeutics for the company's oncology pipeline. These partnerships have been…
Resverlogix Commences Dosing in Phase II Clinical Trial
Resverlogix Corp. recently announced that the first patient has been randomized and dosing has commenced in the Phase III clinical trial BETonMACE with lead drug…
NightstaRx Announces Start of Miami Gene Therapy Study
NightstaRx Ltd recently announced that the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has begun enrolling and dosing subjects…
Juniper Pharma Adds Three New Products to Its Proprietary Pipeline
Juniper Pharmaceuticals, Inc. recently announced details of its portfolio pipeline, focused on three new product candidates to treat women's health conditions, at its Investor Day…
Cancer Genetics Announces Closing Of $12 Million Public Offering
Cancer Genetics, Inc. recently confirmed the closing of its previously announced public offering of 3,000,000 shares of its common stock with 5-year warrants to purchase…
